New study below [1].
I think that some are blindsided by ONJ. The risk is significant with bisphosphonates & Xgeva, & might not be properly explained before treatment. And one's dentist might not be on the ball.
In the U.S., Xgeva is now approved for multiple myeloma, having been found non-inferior to Zometa. My wife has a recurrent solitary plasmacytoma, which is a rare condition related to MM. She has been approved for Xgeva, but recently had dental work. The risk of ONJ is much on our minds.
The new study involved "69 {PubMed} articles comprising 29,437 patients".
"Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients."
There is probably a good paper somewhere that offers sound medical advice on the subject, & the following is just my take on the issue.
Before starting a bisphosphonate or Xgeva, get your mouth looked at by someone who understands the problem.
Delay usage of the drug until remedial work has occurred, but I would delay for at least 3 months. Recovery from an extraction can take a while.
If already on the drug & an extraction, say, becomes necessary, stop the drug but delay treatment for at least 3 months. Meanwhile, treat with an antibiotic if necessary. Wait at least another 3 months before resuming the drug.
The problem with a bisphosphonate is the long half-life. A year after one stops the drug there is still residual risk.
With a very cautious approach, that 3.8% risk of ONJ might be significantly lowered.
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/295...
Dent J (Basel). 2016 Sep 27;4(4). pii: E32. doi: 10.3390/dj4040032.
Prevalence of Medication-Related Osteonecrosis of the Jaw in Patients with Breast Cancer, Prostate Cancer, and Multiple Myeloma.
Rugani P1, Walter C2, Kirnbauer B3, Acham S4, Begus-Nahrman Y5, Jakse N6.
Author information
1
Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria. petra.rugani@medunigraz.at.
2
Oral and Maxillofacial Surgery of the Mediplus Clinic, 55128 Mainz, Germany. walter@mainz-mkg.de.
3
Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria. barbara.kirnbauer@medunigraz.at.
4
Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria. stephan.acham@medunigraz.at.
5
Konzept Pharma Service GmbH, 31084 Freden, Germany. y.begus-nahrmann@konzept-pharma-service.de.
6
Divison of Oral Surgery and Orthodontics, Medical University of Graz, 8010 Graz, Austria. norbert.jakse@medunigraz.at.
Abstract
Medication-related osteonecrosis of the jaw is a known side-effect of antiresorptive therapy in patients with malignant diseases. Nevertheless, the exact pathogenesis is still unknown and published prevalences show a significant range. The aim of the presented paper was to assess the prevalence of osteonecrosis (ONJ) in breast cancer, prostate cancer, and multiple myeloma patients receiving parenteral antiresorptive therapy. For this reason a PubMed search was performed and 69 matching articles comprising 29,437 patients were included in the analysis. Nine-hundred fifty-one cases of jaw necrosis were described. The overall ONJ-prevalence was 2.09% in the breast cancer group, 3.8% in the prostate cancer group, and 5.16% for multiple myeloma patients.
KEYWORDS:
bisphosphonate; breast cancer; denosumab; multiple myeloma; osteonecrosis; prostate cancer
PMID: 29563474 DOI: 10.3390/dj4040032